Skip to main content
. Author manuscript; available in PMC: 2019 Feb 6.
Published in final edited form as: Oncogene. 2018 Aug 6;38(1):88–102. doi: 10.1038/s41388-018-0407-9

Fig. 5. B7-H3 regulates MEK activation through MVP.

Fig. 5

A-B. IP of B7-H3 (or MVP) and control mouse IgG followed by immunoblot analysis of MDA468-B7H3 with whole cell lysates as positive control. C-D. Immunoblot analysis of WCL or IP of MVP and control mouse IgG from lysates from MCF-12A-wt-B7H3, MCF-12A-B7H3-D489(cytosolic domain deletion), MDA468-wt-B7H3, MDA468-B7H3-D489(cytosolic domain deletion). E-F. Cells were transfected with scramble and MVP siRNAs respectively. 48 hours later after transfection, cell lysates were prepared for Western blotting with an antibody against B7-H3, MVP, total MEK, MEK-p, and β-actin(or tubulin) was used as a loading control. G. Immunoblot analysis of IP of MEK and control mouse IgG of lysates from MDA468-vector and MDA468-B7H3. H. Immunoblot analysis of IP of MVP (or B7-H3) and control mouse IgG of lysates from MDA468-vector and MDA468-B7H3. I. Immunoblot analysis of IP of MEK and control mouse IgG of lysates from MDA468-B7H3(scramble) and MDA468-B7H3(MVP shRNA).